Background {#Sec1}
==========

Benzimidazole is a dicyclic organic scaffold having imidazole (containing two nitrogen atoms at adjoining site) attached with benzene ring. Benzimidazole considered as potential bioactive heterocyclic aromatic compounds with a variety of biological activities like anti-inflammatory \[[@CR1]\], antiparasitic \[[@CR2]\], antimalarial \[[@CR3]\], antimycobacterial \[[@CR4]\], antineoplastic \[[@CR5]\], antiviral \[[@CR6]\], antihypertensive \[[@CR7]\] and anticonvulsant \[[@CR8]\] activities. Benzimidazole (synthesis (A); Fig. [1](#Fig1){ref-type="fig"}) and its derivatives are the most resourceful classes of molecules against microorganisms \[[@CR9]\]. The increase in antimicrobial resistance to existing drugs necessitated the search for new molecules for the treatment of bacterial infections \[[@CR10], [@CR11]\]. Currently, a number of benzimidazole containing drugs are available in market namely: albendazole (i), mebendazole (ii), thiabendazole (iii) ridinalazon (iv) and cyclobendazole (v) (marketed drugs (B); Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Synthesis of benzimidazole **(A)** and marketed drugs **(B)**

Biological profile {#Sec2}
==================

Antimicrobial activity {#Sec3}
----------------------

Ansari et al. synthesized 2-substituted-1*H*-benzimidazole derivatives by nucleophilic substitution reaction and evaluated their antimicrobial activity against selected microbial species. The compounds **1a**, **1b**, **1c** and **1d** showed good antibacterial activity as well as compound **1c** showed good antifungal activity (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). SAR study inferred that at 2-position of oxadiazole ring increased side chain carbon atom number causes an enhanced the antimicrobial activity toward *C. albicans*, *S. aureus* and *B. subtilis* and also the *para*-substituted phenyl nucleus supported the activity \[[@CR9]\].Table 1Antimicrobial activity of compounds (1a--1d)CompoundsAntibacterial activity\
Microbial strains (MIC = µg/mL)Antifungal activity (ZI mm)*S. aureusB. subtilisS. mutansE. coliP. aeruginosaS. typhiC. albicansA. nigerA. flavus***1a**448646416------**1b**48432\> 12832------**1c**244\> 128NENE22--2810--1522--28**1d**284166416------**Ciprofloxacin**≤ 1≤ 1NE≤ 1NENE------**Ampicillin**2224\> 128\> 128------**Amphotericin B**------------22--2822--2822--28NE: not exercised Fig. 2Molecular structures of compounds **(1a**--**1d, 2a**--**2i)**

Ansari et al. reported a series of 2-mercaptobenzimidazole derivatives and screened for its in vitro antimicrobial activity (using cup-plate agar diffusion method) against selected microbial species i.e. *E. coli*, *B. subtilis*, *A. flavus*, *C. albicans* and *A. niger.* Structure activity relationship studies revealed that compounds having *o*-Cl (**2f** and **2h**), *o*-CH~3~ (**2g** and **2i**), --OH (**2b**, **2c** and **2d**) and *p*-NH~2~ (**2e**) groups in phenyl ring as well as compound **2a** without substitution displayed significant antibacterial potential which is comparable to the reference drugs (Table [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}) \[[@CR12]\].Table 2Antimicrobial activity of compounds (2a--2i)Comp.Microbial species(MIC = µg/mL)ZI mm (30 µg/mL)110100200500*C. albicansA. nigerA. flavus***2a***B. subtilis*+++−−−16--2122--2822--28**2b**+++−−−−−−**2c**++PG−−16--2116--2116--21**2d**+PG−−−−−−**2e**+PG−−−−−−**2f***E. coli*+++−−−−−−**2** **g**+++−−−−−−**2** **h**+++−−−−−−**2i**+++−−−−−−**Ampicillin**+−−−−−−−**Amphotericin B**−−−−−22--2822--2822--28Total inhibition (no growth of microorganism): (−); insufficient growth compared to control: (PG); average growth compared to control: (+); no inhibition: (++)

Arjmand et al. synthesized novel Cu(II) complex benzimidazole derivative via condensation of 2-mercaptobenzimidazole with diethyloxalate and screened for their antimicrobial activity against bacterial (*E. coli, S. aureus*) and fungal (*A. niger*) species. Compound **3a** exhibited highest activity against the bacterial as well inhibited the growth of fungal species (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR13]\].Table 3Antimicrobial activity of Cu(II) complex 3aCompoundZI mm (30 µg/mL)Growth inhibition concentration of compound \[complex\] × 10^−5^ M*S. aureusE. coliA. niger*Bacteria\
(*S. aureus* and *E. coli*)Fungus\
(*A. niger*)**3a**\[C~20~H~22~N~8~S~2~Cu\]Cl~2~1.71.7191719133.4231923205.1252225266.8282627 Fig. 3Molecular structures of compounds **(3a**, **4a**--**4b**, **5a**--**5c**, **6a**--**6c**, **7a**--**7d)**

A novel series of benzimidazole derivatives was reported by Ayhan-Kilcigil et al. and evaluated for its antimicrobial potential against selected strains by the tube dilution technique. Compound, **4a** showed significant antimicrobial potential against *B. subtilis* and *P. aeruginosa* with MIC values of 12.5 and 25 µg/mL, respectively which is comparable to ampicillin (MIC = 6.25 and 25 µg/mL) as well **4a** and **4b** (Fig. [3](#Fig3){ref-type="fig"}) showed good antifungal activity with MIC values of 6.25 and 12.5 µg/mL (*C. albicans*) as comparable with fluconazole (MIC = 6.25 µg/mL) and miconazole (MIC = 3.125 µg/mL) \[[@CR14]\].

Bandyopadhyay et al. synthesized new class of 1,2-disubstituted benzimidazole derivatives using Al~2~O~3~--Fe~2~O~3~ nanocrystals as heterogeneous catalyst under mild reaction conditions and evaluated for its antibacterial activity (Kirby--Bauer disc diffusion method) against *B. cereus*, *V. cholerae*, *S. dysenteriae, S. aureus* and *E. coli*. Compounds, **5a, 5b** and **5c** (Fig. [3](#Fig3){ref-type="fig"}) showed good activity as compared to standard ciprofloxacin. Additionally, compounds **5a** and **5c** showed absolute bactericidal activity against tested strains within 24 h, whereas ciprofloxacin kill those bacteria in 48 h (Table [4](#Tab4){ref-type="table"}) \[[@CR15]\].Table 4Antibacterial activity of compounds (5a--5c)Comp.Microorganisms (ZI mm)*E. coliV. choleraeS. dysenteriaeS. aureusB. cereus***5a**1933231022**5b**22131922--**5c**--231110--**Ciprofloxacin**3224141514

Barot et al. developed some novel benzimidazole derivatives and evaluated for their antimicrobial potential towards *P. aeruginosa*, *E. coli*, *B. cereus*, *K. pneumonia*, *S. aureus*, *E. faecalis*, *C. albicans*, *A. niger* and *F. oxyspora* and compared to standard drugs ofloxacin metronidazole and fluconazole. From this series, compounds **6a** and **6b** revealed good antibacterial activity where as compound **6c** showed significant antifungal activity (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR10]\].Table 5Antimicrobial activity of compounds (6a--6c)Comp.Microorganisms (MIC in µg/mL)*B. cereusE. faecalisS. aureusE. coliP. aeruginosaK. pneumoniaC. albicansA. nigerF. oxyspora***6a**57710109------**6b**5788811------**6c**------------878**Ofloxacin**223445------**Metronidazole**333344------**Fluconazole**------------233

Desai et al. reported a series of 2-mercaptobenzimidazole and *β*-lactum segment derivatives containing --CONH-- and evaluated for its in vitro antibacterial (Kirby--Bauer disc diffusion technique) and antifungal potentials against tested microorganisms using streptomycin and flucanozole as standards. Among the synthesized compounds, **7a** displayed tremendous inhibitory activity against *B. subtilis*, **7b** showed excellent activity against *E. coli* and *S. aureus*, **7c** showed considerable activity against *A. niger* and **7d** showed significant activity against *C. krusei* (Table [6](#Tab6){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}) \[[@CR16]\].Table 6Antimicrobial activity results of compounds (7a--7d)CompoundsMicroorganismsBacteria (ZI mm)Fungi (MIC = µg/mL)*B. subtilisS. aureusE. coliC. albicansC. kruseiA. niger***7a**20--2515--2015--20------**7b**15--2020--2520--25------**7c**------150100150**7d**------150150100**Streptomycin**25--3025--3025--30------**Fluconazole**------505050

Desai et al. reported new benzimidazoles bearing 2-pyridone and evaluated for their antimicrobial activity against *S. pyogenes*, *E. coli*, *S. aureus*, *P. aeruginosa*, *C. albicans*, *A. clavatus* and *A. niger* by conventional broth dilution technique. Among the synthesized compounds, **8a**, **8b**, **8c** and **8d** (Table [7](#Tab7){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) having electron withdrawing group (nitro) at the *m*-position enhanced the antibacterial activity and compared to chloramphenicol while compound **8e** displayed most effective antifungal activity and comparable to standard ketoconazole \[[@CR11]\].Table 7Antimicrobial activity results of compounds (8a--8e)Comp.Microorganisms (MIC = µg/mL)*S. aureusS. pyrogensE. coliP. aeruginosaC. albicansA. nigerA. clavatus***8a**12.5 ± 1.0512.5 ± 1.2125 ± 1.3525 ± 2.80500 ± 1.57100 ± 1.24250 ± 2.78**8b**50 ± 1.5450 ± 1.31100 ± 2.65100 ± 1.61500 ± 2.15250 ± 2.21250 ± 1.24**8c**12.5 ± 1.4825 ± 2.1525 ± 1.3525 ± 1.15100 ± 1.64500 ± 1.85250 ± 1.32**8d**25 ± 1.2150 ± 1.8125 ± 1.5450 ± 1.51250 ± 1.32\> 1000500 ± 2.32**8e**62.5 ± 1.35100 ± 1.65125 ± 1.42125 ± 1.7125 ± 1.4150 ± 1.1462.5 ± 1.35**Chloram-phenicol**50 ± 1.2450 ± 2.0450 ± 1.0050 ± 2.06------**Ketoconazole**--------50 ± 0.5050 ± 1.2050 ± 1.10 Fig. 4Molecular structures of compounds **(8a**--**8e**, **9a**, **10a**--**10b**, **11a**--**11c**, **12a)**

Dolzhenko et al. prepared novel 3,4-dihydro \[[@CR1], [@CR3], [@CR5]\] triazino\[1,2-*a*\]benzimidazole compounds and screened for their in vitro antibacterial activity by twofold serial dilution technique. Compound **9a** exhibited good antibacterial potential as compared to standard drug tetracyclin (Table [8](#Tab8){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}**)** \[[@CR17]\].Table 8Antibacterial activity of the fluorinated compound 9aCompoundMicrobial strains (MIC = µg/mL)*S. aureusB. subtilisB. megateriumK. aerogenesE. coli***9a**2525\>25\> 25\> 25**Tetracycline**0.630.630.631.251.25

Goker et al. developed novel substituted benzimidazole carboxamidine molecules and assessed for their antibacterial activity by tube dilution method against selected microbes. Compounds **10a** and **10b** displayed significant antibacterial activity (Table [9](#Tab9){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) as comparable to standard drugs (ampicillin and sultamicillin) \[[@CR18]\].Table 9In vitro antibacterial activity of compounds (10a--10b)CompoundsMicroorganisms MIC (µg/mL)*S. aureus*MRSAMRSA (isolate from blood)MRSA (isolate from wound)**10a**0.780.780.391.56**10b**0.390.780.390.78**Ampicillin**0.78505050**Sultamicillin**0.39252525

Gumus et al. synthesized platinum(II) complexes with substituted benzimidazole ligands and evaluated for their antimicrobial potential against *S. aureus*, *P. aeruginosa, S. faecalis*, *E. coli* and *C. albicans* using the macro dilution broth method. Complex **11a** (MIC = 100 µg/mL) exhibited good antibacterial activity against *S*. *faecalis*, **11b** (Mpyrb- methyl *α*-pyridyl benzimidazole, MIC = 50 µg/mL) against *C*. *albicans* and **11c** (Merb- mercaptobenzimidazole, MIC = 50 and 100 µg/mL) (Fig. [4](#Fig4){ref-type="fig"}) found active against *S*. *faecalis* and *S*. *aureus* \[[@CR19]\].

Guven et al. reported a new class of benzimidazole and phenyl-substituted benzyl ethers and evaluated for its antimicrobial potential against selected microbial species. Among the synthesized derivatives, compound **12a** (Table [10](#Tab10){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) exhibited good antibacterial activity and comparable to the standard drug \[[@CR20]\].Table 10In vitro antimicrobial activity of compounds (12a)CompoundsMicrobial strains MIC (µg/mL)*S. aureus*MRSA*C. albicansC. krusei***12a**3.126.2512.512.5**Ampicillin**0.7825----**Fluconazole**----0.7825**Miconazole**----0.190.78

Hu et al. designed new bis-benzimidazole diamidine compounds and evaluated for their antibacterial activity against tested species and compared to standard drugs (penicillin G, vancomycin and ciprofloxacin). Compound **13a** exhibited the potent antibacterial activity than vancomycin (Table [11](#Tab11){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR21]\].Table 11Antibacterial results of compound 13aCompoundStrainsMIC (µg/mL)Penicillin-GCiprofloxacinVancomycin**13a***S. aureus*0.25--0.510.50.5*S. aureus* ^a^0.5\> 3281*S. aureus* ^b^0.25--0.5\> 32≤ 0.121*S. epidermidis*\< 0.0632≤ 0.121*S. epidermidis* ^c^0.12532≤ 0.121*S. pneumoniae*\< 0.06\< 0.060.51*E. faecalis* ^d^0.25--0.540.5\> 64*E. faecium* ^d^0.12\> 32\> 64\> 64*B. subtils*0.12\< 0.06≤ 0.120.12--0.5*B. cereus*0.124-- \> 32≤ 0.121-- ≤ 0.12*B. fragile*0.5--14--80.54--8*C. perfringens*0.25--0.5≤ 0.06--0.120.250.12--0.25^a^MDRSA^b^MRSA^c^MRSE^d^VRE Fig. 5Molecular structures of compounds **(13a**, **14a**--**14c**, **15a**, **16a**, **17a**, **18a**, **19a-19b**, **20a--20b)**

Jardosh et al. developed a novel series of pyrido\[1,2-*a*\]benzimidazole derivatives and assessed for its in vitro antimicrobial activity against *S. typhi*, *S. pneumoniae*, *E. coli*, *C. tetani*, *V. cholera*, *B. subtilis*, *C. albicans* and *A. fumigatus* using broth micro dilution technique. Among the synthesized derivatives, compounds **14a**--**14c** (Fig. [5](#Fig5){ref-type="fig"}) displayed the good antimicrobial activity and compared to standard drugs (Table [12](#Tab12){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}**)** \[[@CR22]\].Table 12In vitro antimicrobial activity of benzimidazole compounds (14a--14c)CompoundsMicroorganisms (MIC = µg/mL)*B. subtilisC. tetaniS. pneumoniaeE. coliS. typhiV. choleraA. fumigatusC. albicans***14a**100200100200250250\> 1000250**14b**50020020025025050200\> 1000**14c**25025025062.5200100\> 1000250**Ciprofloxacin**5010050252525----**Chloramphenicol**505050505050----**Norfloxacin**1005010101010----**Ampicillin**250250100100100100----**Griseofulvin**------------100500

Kalinowska-Lis et al. synthesized silver (I) complexes of benzimidazole and screened for their antimicrobial activity against *S. epidermidis*, *S. aureus* and *C. albicans*. In this series, compound **15a** (Fig. [5](#Fig5){ref-type="fig"}) exhibited good antifungal but moderate antibacterial activity as compared to standard drugs AgNO~3~ and silver sulfadiazine (AgSD) (Table [13](#Tab13){ref-type="table"}) \[[@CR23]\].Table 13Antimicrobial activity results of compound 15aCompound 15aMicroorganisms*S. aureusS. epidermisC. albicans*MICMBCMICMBCMICMBCmg/LµM/Lmg/LµM/Lmg/LµM/Lmg/LµM/Lmg/LµM/Lmg/LµM/L**\[Ag(2-CH** ~**2**~ **OHbim)** ~**2**~ **\]NO** ~**3**~8017190193801719019310202043**AgNO** ~**3**~158825147158820118105930117**Silver sulfadiazine (AgSD)**6016890252401128022420562056

Kankate et al. developed novel benzimidazole analogues and screened for their in vitro (tube dilution technique) and in vivo antifungal activity (kidney burden test) against *C. albicans*. Compound **16a** (Fig. [5](#Fig5){ref-type="fig"}) exhibited superior in vitro antifungal activity with MIC value of 0.0075 µmol/mL as comparable to fluconazole while in vivo activity was significantly less (P \< 0.001) \[[@CR24]\].

Khalafi-Nezhad et al. synthesized some chloroaryloxyalkyl benzimidazole derivatives and screened for their in vitro antimicrobial activity against *S. typhi* and *S. aureus* using disk diffusion method. Compound **17a** showed good antibacterial activity against the tested microbial species (Table [14](#Tab14){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR25]\].Table 14Antibacterial screening results of compound 17aCompoundMicroorganisms (MIC = µg/mL)*S. aureusS. typhi***17a**2224**Chloramphenicol**1620**Hexachlorophene**101

Klimesova et al. developed a chain of 2-alkylsulphanylbenzimidazoles and evaluated for its in vitro antimycobacterial and antifungal activities against selected strains using isoniazide and ketoconazole as standards. Among the synthesized compounds, **18a** exhibited significant antimycobacterial and antifungal activities (Table [15](#Tab15){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR26]\].Table 15Antimycobacterial screening results of compound 18a (MIC = µmol/L)CompoundBacterial strainsFungal strains*M. tuberculosis*\
MY 331/88*M. kansasii*\
My 235/80*M. kansasii*\
My 6509/96*M. avium*\
(*M.* My 330/88)*T. mentagrophytes* 445*A. corymbifera* 272*A. fumigates* 23114 days21 days7 days14 days21 days7 days14 days21 days14 days21 days72 h24 h24 h**18a**444884888862----**Isoniazide**0.51\> 250\> 250\> 250244\> 250\> 250------**Ketoconazole**--------------------0.9831.257.81

Koc et al. synthesized few tripodal-benzimidazole derivatives and evaluated for their antibacterial activity against *S. aureus*, *B. subtilis* and *E. coli* by standard disk diffusion technique using gentamycin as reference. Among the synthesized compounds, **19a** and **19b** exhibited good antibacterial activity toward *E. coli*, *S. aureus* and *B. subtilis* (Table [16](#Tab16){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR27]\].Table 16Antimicrobial activity of compounds (19a--19b)CompoundsMicroorganisms (ZI/mm^2^)*E. coliB. subtilisS. aureus***19a**799**19b**7910**Gentamycin**161618

Kucukbay et al. synthesized new electron-rich olefins benzimidazole compounds and evaluation for their in vitro antimicrobial activity against the selected microbial species and compared to standard drug. Among the prepared compounds, **20a** and **20b** were found to be most effective against *C. albicans* and *C. tropicalis* (Table [17](#Tab17){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}) \[[@CR28]\].Table 17Antimicrobial results of compounds (20a--20b)CompoundMicroorganisms (MIC = µg/mL)BacteriaFungi*E. FaecalisS. aureusE. coliP. aeruginosaC. albicansC. tropicalis***20a**2002005050----**Ampicillin**0.780.393.12\> 75----**20b**--------5050**Fluconazole**--------1.251.25

Kumar et al. developed a new series of substituted benzimidazole scaffolds and screened for its in vitro antibacterial potential against *S. aureus* and *S. typhimurium* and compared to cephalexin as standard. Compounds, **21a** and **21b** exhibited good antibacterial activity against *S. typhimurium* whereas showed pitiable activity against *S. aureus* (Table [18](#Tab18){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR29]\].Table 18Antibacterial activity of compounds (21a--21b)CompoundsConcentration (µg/mL) (*S. typhimurium*)0.1110100200500App. MIC**21a**++PGPG−−200**21b**+++PG−−200**Cephalexin**+++++PG−−200Full inhibition, no growth of organism: −; meager growth compared to controls: PG; average growth compared to controls: +; confluent growth, inhibition: ++ Fig. 6Molecular structures of compounds **(21a**--**21b**, **22a**--**22b**, **23a**, **24a**, **25a**, **26a**--**26d)**

Kumar et al. reported a series of trisubstituted benzimidazole molecules and screened for its antimicrobial potential against *F. tularensis* LVS strain using Microplate Alamar Blue assay. Compounds, **22a** and **22b** (Fig. [6](#Fig6){ref-type="fig"}) exhibited promising antimicrobial activity with MIC values of 0.35 and 0.48 µg/mL \[[@CR30]\].

Lopez-Sandoval et al. reported a series of cobalt (II) and zinc (II) coordination complexes with benzimidazole and evaluated for its antimicrobial potential by disk diffusion method and antibiotics microbial assays (U.S.P 23) against *P. aeruginosa*, *E. coli*, *S. typhi*, *M. luteus*, *S. aureus* and *P. vulgaris*. Among the synthesized complexes, complex **23a** exhibited good activity toward *M. luteus* and *E. coli* (Table [19](#Tab19){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR31]\].Table 19Antibacterial activity of compound 23aCompound 23aMicroorganisms*M. luteusE. coli*ZI (mm)MIC (µg/mL)ZI (mm)MIC (µg/mL)**\[Zn(2aminobenzimidazole)** ~**2**~ **Cl** ~**2**~ **\]·0.5H** ~**2**~ **O**101.611.13.9**Amoxicillin**10.40.125----**Chloramphenicol**----11.31.6

Mehboob et al. reported a class of second generation benzimidazole derivatives and screened for its antibacterial activity against *S. aureus*, MRSA, *F. tularensis* and *E. coli*. Among the synthesized compounds, **24a** exhibited good antibacterial activity against selected bacterial strains (Table [20](#Tab20){ref-type="table"}, Fig. [6](#Fig6){ref-type="fig"}) \[[@CR32]\].Table 20Compound 24a MIC/MBC (µg/mL) values of compound 24aCompoundMicroorganisms*F. tularensisS. aureus*MRSA*E. coliE. coli* TolC-**24a**5.5/12.5\> 12.5\> 12.5\> 12.512.5MBCs were not determined for compounds with MICs ≥ 12.5 µg/mL. *E. coli* TolC- is the *E. coli* TolC efflux pump knockout mutant

Mohamed et al. reported a class of seven transition metal complexes of benzimidazole and assessed for its antifungal activity against *F. solani*, *R. solani* and *S. rolfesii*. Among the synthesized metal complexes, cobalt complex **25a** (Fig. [6](#Fig6){ref-type="fig"}) displayed the highest fungicidal activity with lowest EC~50~ values of 353.55, 205.45 and 196.84 ppm for the *F. solani*, *R. solani* and *S. rolfesii*, respectively \[[@CR33]\].

Moreira et al. reported a series of bis-benzimidazole conjugates and screened for its antibacterial activity against selected microbes. Among the synthesized derivatives, compounds **26a**, **26b** and **26c** possessed excellent activity against Gram-positive bacteria with MIC~90~ values between 0.06 and 1 mg/L. Compounds **26c** and **26d** exhibited significant activity against *M. tuberculosis* H37Rv with MIC value of 2 mg/L and 1 mg/L, respectively (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR34]\].

Noolvi et al. developed a class of 1*H*-benzimidazole azetidine-2-one scaffolds and assessed for its antibacterial activity against selected bacteria (*S. aureus*, *B. pumillus*, *E. coli* and *P. aeruginosa*). The MIC and ZI of the synthesized compounds was determined by agar diffusion technique. Compounds **27a**--**27e** showed significant antibacterial activity as comparable to ampicillin (Table [21](#Tab21){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR35]\].Table 21In vitro antimicrobial activity of compounds (27a--27e)CompoundsMicroorganisms (ZI mm)Microorganisms (MIC = µg/mL)*S. aureusB. pumillusE. coliP. aeruginosaS. aureusB. pumillusE. coliP. aeruginosa***27a**11.310.210.810.6--------**27b**10.910.511.211.0--------**27c**13.211.213.610.9--------**27d**13.211.512.811.325255075**27e**--------25255050**Ampicillin**14.812.815.213.46.512.52525Fig. 7Molecular structures of compounds **(27a**--**27e**, **28a**--**28c**, **29a**--**29b**, **30a**--**30b**, **31a)**

Ozden et al. synthesized a chain of benzimidazole-5-carboxylic acid alkyl esters and evaluated for its antimicrobial activity against methicillin resistant *E. coli*, MRSA, *S. aureus*, *S. faecalis*, MRSE and *C. albicans*. Compounds **28a**, **28b** and **28c** exhibited promising antimicrobial activity as compared to reference drugs (Table [22](#Tab22){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR36]\].Table 22Antibacterial and antifungal activities of compounds (28a--28c)CompoundsMinimum inhibitory concentration (µg/mL)*S. aureus*MRSA*S. faecalis*MRSE*E. coliC. albicans***28a**0.780.786.251.56\> 5012.5**28b**1.560.783.120.78\> 5012.5**28c**1.560.393.121.56\> 506.25**Ampicillin**0.39500.78------**Sultamicillin**0.78251.563.12----**Gentamisin**--------0.78--**Fluconazole**----------1.56

Ozkay et al. developed a series of benzimidazole compounds with hydrazone moiety and assessed for its in vitro antimicrobial potential against bacterial (*E. faecalis*, *B. subtilis, L. cytogenes, S. aureus*, *P. aeruginosa*, *K. pneumoniae*, *E. coli* ATCC 35218, *E. coli* ATCC 25922, *S. typhimurium, P. vulgaris*) and fungal (*C. albicans*, *C. tropicalis*, *C. globrata*) species by twofold serial dilutions technique taking chloramphenicol and ketocanozole as reference drugs. In this series, compounds, **29a** and **29b** showed promising antibacterial and antifungal activities as compared to standard drugs (Tables [23](#Tab23){ref-type="table"} and [24](#Tab24){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR37]\].Table 23MIC values (µg/mL) of compounds (29a--29b) against Gram-negative bacteriaCompoundMicroorganisms*E. coli*\
ATCC 35218*E. coli*\
ATCC 25922*P. vulgarisS. typhimuriumK. pneumoniaeP. aeruginosa***29a**25100256.2512.525**29b**25502512.512.525**Chloramphenicol**12.512.55012.512.550 Table 24MIC values (µg/mL) of compounds (29a--29b) against Gram-positive bacteria and fungal strainsCompoundsMicroorganisms*L. monocytogenesS. aureusE. faecalisB. subtilisC. albicansC. globrataC. tropicalis***29a**10012.512.525505050**29b**2002512.52510010050**Chloramphenicol**5012.512.512.5------**Ketoconazole**--------502550

Padalkar et al. synthesized a new class of 2-(1*H*-benzimidazol-2-yl)-5-(diethylamino) phenol derivatives and screened for its antimicrobial potential against *S. aureus*, *E. coli*, *A. niger* and *C. albicans* using serial dilution method. Among them, compounds, **30a** (2-(1*H*-benzo\[*d*\]imidazol-2-yl)-5-(diethylamino)phenol) and **30b** (5-(diethylamino)-2-(5-nitro-1*H*-benzo\[*d*\]imidazol-2-yl)phenol) displayed significant activity against tested bacterial species and their activity results are similar to the reference drug (Table [25](#Tab25){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}) \[[@CR38]\].Table 25Antimicrobial activity of compounds (30a--30b)CompoundsMicroorganisms \[MIC (µg/mL)\]*E. coliS. aureusC. albicansA. niger***30a**6060130130**30b**6060130250**Streptomycin**6060----**Fluconazole**----6060

Seenaiah et al. reported a series of benzimidazole derivatives and screened for its antimicrobial activity against selected bacterial and fungal species by agar well diffusion (ZI) and broth dilution methods (MIC). In this series, compound **31a** displayed promising activity against tested microorganisms as comparable to standard drugs (Tables [26](#Tab26){ref-type="table"}, [27](#Tab27){ref-type="table"}, [28](#Tab28){ref-type="table"} and Fig. [7](#Fig7){ref-type="fig"}) \[[@CR39]\].Table 26Antimicrobial activity of compound 31aCompoundZI (mm)Gram + veGram − ve*S. aureusE. coliP. aeruginosa*25 µg/mL50 µg/mL100 µg/mL25 µg/mL50 µg/mL100 µg/mL25 µg/mL50 µg/mL100 µg/mL**31a**23 ± 326 ± 129 ± 228 ± 132 ± 435 ± 322 ± 125 ± 327 ± 2**Ciprofloxacin**22 ± 124 ± 327 ± 130 ± 235 ± 338 ± 225 ± 128 ± 230 ± 3 Table 27Antifungal activity of compound 31aCompoundFungus (ZI mm)*A. nigerP. chrysogenum*25 µg/mL50 µg/mL100 µg/mL25 µg/mL50 µg/mL100 µg/mL**31a**27 ± 130 ± 332 ± 133 ± 235 ± 138 ± 2**Ketoconazole**31 ± 233 ± 336 ± 335 ± 136 ± 238 ± 3 Table 28Antimicrobial activity of compound 31aCompoundMIC (MBC/MFC) µg/mL*S. aureusE. coliP. aeruginosaA. nigerP. chrysogenum***31a**12.5 (25)50 (200)12.5 (100)12.5 (100)12.5 (25)**Ciprofloxacin**12.512.512.5----**Ketoconazole**------6.2512.5

Tiwari et al. designed a new series of benzimidazole scaffolds and evaluated for its in vitro antifungal potential against *A. flavus* and *A. niger* by agar plate method. From the synthesized derivatives, compounds **32a** and **32b** showed excellent antimicrobial activity as comparable to reference (amphotericin B) (Table [29](#Tab29){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR40]\].Table 29Antifungal activity of benzimidazole derivatives (32a--32b)CompoundsConcentration (µg/mL)Microorganisms*A. flavusA. niger*Colony diameterInhibition (%)Colony diameterInhibition (%)**32a**100.873.31.060.3200.676.70.876.8500.588.30.584.6**32b**101.260.80.860.7201.173.40.783.2500.792.10.783.6**Amphotericin B**203.086.42.079.9 Fig. 8Molecular structures of compounds **(32a**--**32b**, **33a**--**33d**, **34a**, **35a**, **36a**--**36b**, **37a**--**37b)**

Tuncbilek et al. designed some novel benzimidazole derivatives and screened for their antimicrobial potential toward *E. coli*, *B. subtilis*, MRSA (clinical and standard isolates), *S. aureus* and *C. albicans*. Compounds **33a**--**33d** displayed the excellent antibacterial activity as comparable to reference drugs (sultamicillin, ciprofloxacin and ampicillin) (Table [30](#Tab30){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR41]\].Table 30Antibacterial and antifungal activities of compounds (33a--33d)CompoundsMicroorganisms (MIC = µg/mL)*S. aureus*MRSA^a^MRSA^b^*E. coliB. subtilisC. albicans***33a**3.126.256.25506.256.25**33b**3.123.123.12506.256.25**33c**3.123.123.12505012.5**33d**3.123.123.12506.2512.5**Sultamicillin**0.392525--0.78--**Ampicillin**0.785050------**Ciprofloxacin**0.786.2512.50.190.09--**Fluconazole**----------1.56^a^MRSA---standard^b^MRSA---clinical isolate

Zhang et al. synthesized a chain of new actinonin derivatives of benzimidazole and evaluated for its antimicrobial potential against *S. lutea*, *K. pneumoniae* and *S. aureus* using microbroth dilution method. Compound **34a** ((*R*)-3-(4-(1*H*-benzo\[*d*\]imidazol-2-yl)but-1-en-2-yl)-*N*-hydroxy heptanamide) showed potent antibacterial activity against tested microorganism than the standard drug (Table [31](#Tab31){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR42]\].Table 31Antibacterial activity of compound 34aCompoundMicroorganisms (MIC = µg/mL)*S. aureusK. pneumoniaS. lutea***34a**20.54**Cefoperazone**0.250.250.25

Zhang et al. reported a class of substituted benzimidazole compounds and screened for its antimicrobial potential against two fungal, four Gram-positive and five Gram-negative bacterial strains through twofold serial dilution technique. Among them, compound **35a** exhibited remarkable antimicrobial activity even better than the standards fluconazole, chloromycin and norfloxacin (Tables [32](#Tab32){ref-type="table"}, [33](#Tab33){ref-type="table"} and Fig. [8](#Fig8){ref-type="fig"}) \[[@CR43]\].Table 32Antibacterial and antifungal activities of compound 35aCompoundMicroorganisms (MIC = µg/mL)Bacteria (Gram + ve)FungiMRSA*S. aureusB. subtilisM. luteusC. albicansC. mycoderma***35a**2241642**Chloromycin**1616328----**Norfloxacin**80.512----**Fluconazole**--------14 Table 33Antibacterial activity (MIC = µg/mL) of compound 35aCompoundMicroorganisms (Gram − ve bacteria)*E. coliS. dysenteriaeP. aeruginosaB. proteusE. typhosa***35a**48484**Chloromycin**3232323232**Norfloxacin**1641684

Zhang et al. designed a novel class of benzimidazole type of fluconazole compounds and evaluated for its antimicrobial activity by two-fold serial dilution technique. Among them, compounds **36a** and **36b** exhibited the potent antimicrobial efficiency as compared to standards norfloxacin, chloromycin and fluconazole (Tables [34](#Tab34){ref-type="table"} and [35](#Tab35){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR44]\].Table 34Antibacterial activity (MIC = µg/mL) of compounds (36a--36b)CompoundsMicroorganisms (bacteria)*S. aureus*MRSA (N315)*B. subtilisM. luteusB. proteusE. coliP. aeruginosaB. typhi***36a**216482242**36b**8168816321616**Chloromycin**81632832161632**Norfloxacin**12141111 Table 35Antifungal activity (MIC = µg/mL) of compound 36aCompoundMicroorganisms (fungi)*C. albicansC. mycodermaC. utilisS. cerevisiaeA. flavus***36a**22828**Fluconazole**14816256

Madabhushi et al. synthesized a new series of benzimidazole functionalized chiral thioureas and assessed for their antimicrobial activity against *S. aureus*, *B. subtilis*, *S. aureus* MLS16, *M. luteus*, *K. planticola*, *E. coli* and *P. aeruginosa*. Among them, compounds **37a** and **37b** displayed excellent antibacterial activity toward selected microorganisms (Table [36](#Tab36){ref-type="table"}, Fig. [8](#Fig8){ref-type="fig"}) \[[@CR45]\].Table 36Antibacterial activity of compounds (37a--37b)CompoundsMicrobial strains (MIC = µg/mL)*S. aureusB. subtilisS. aureus MLS16M. luteusK. planticolaE. coliP. aeruginosa***37a**25.012.512.525.025.012.56.25**37b**25.012.512.56.2512.512.56.25**Neomycin**12.512.512.512.512.512.512.5

Yadav et al. synthesized some 2-(1-benzoyl-1*H*-benzo\[*d*\]imidazol-2-ylthio)-*N*-substituted acetamide derivatives and evaluated for their antimicrobial activity (MIC and MBC/MFC) against tested strains by tube dilution method using cefadroxil and fluconazole as references. Among the synthesized compounds, **38a**, **38b** and **38c** emerged out as excellent antimicrobial agents (Tables [37](#Tab37){ref-type="table"}, [38](#Tab38){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) \[[@CR46]\].Table 37Antimicrobial activity of compounds (38a--38c)CompoundsMicroorganisms (MIC = µM/mL)*S. aureusB. cereusB. subtilisS. typhiE. coliC. albicansA. niger***38a**0.0270.0270.0270.0270.0270.0130.027**38b**0.0270.0270.0270.0270.0270.0130.027**38c**0.0270.0270.0270.0270.0270.0130.027**Cefadroxil**0.370.370.370.370.37----**Fluconazole**----------0.470.47 Table 38Antimicrobial activity (MBC/MFC) of compounds (38a--38c)CompoundsMicroorganisms (µg/mL)*S. aureusB. cereusB. subtilisS. typhiE. coliC. albicansA. niger***38a**50\> 50\> 50\> 50\> 5050\> 50**38b**\> 50\> 50\> 5050\> 5050\> 50**38c**50\> 50505050\> 50\> 50 Fig. 9Molecular structures of compounds **(38a**--**38c**, **39a**--**33b**, **40a**, **41a**, **42a**, **43a**--**43b**, **44a**--**44b**, **45a--45b)**

Yadav et al. reported a class of novel benzimidazole derivatives and screened for its antimicrobial potency (MIC, MBC/MFC) against *S. aureus*, *B. subtilis*, *E. coli*, *C. albicans*, *A. niger* by tube dilution method using norfloxacin and fluconazole standard drugs. Compounds **39a** and **39b** showed prominent antimicrobial activity (Tables [39](#Tab39){ref-type="table"}, [40](#Tab40){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) \[[@CR47]\].Table 39Antimicrobial activity (MIC = µM/mL) of compounds (39a--39b)CompoundsMicroorganisms*S. aureusB. subtilisE. coliC. albicansA. niger***39a**0.0270.0270.0130.0270.027**39b**0.0290.0290.0150.0070.029**Norfloxacin**0.470.470.47----**Fluconazole**------0.500.50 Table 40Antimicrobial activity (MBC/MFC) of compounds (39a--39b)CompoundsMicroorganisms (µg/mL)*S. aureusB. subtilisE. coliC. albicansA. niger***39a**\> 0.108\> 0.1080.0130.0540.054**39b**\> 0.116\> 0.1160.0150.0150.116

Yadav et al. designed a series of new benzimidazole derivatives and accessed for its antimicrobial potential against *S. aureus*, *B. subtilis*, *E. coli*, *C. albicans*, *A. niger* by tube dilution method. In this series, compound **40a** displayed the most potent antimicrobial activity (Table [41](#Tab41){ref-type="table"}, Fig. [9](#Fig9){ref-type="fig"}) \[[@CR48]\].Table 41Antimicrobial activity (MIC = µM/MBC/MFC = µg/mL) of compound 40aCompoundMicroorganisms*S. aureusB. subtilisE. coliC. albicansA. niger***40a**0.032/\> 500.032/\> 500.032/\> 500.016/\> 500.032/\> 50**Cefadroxil**0.3450.3450.345----**Fluconazole**------0.400.82

Kerimov et al. developed new benzimidazole derivatives and evaluated for their antifungal activity against *C. albicans* and *C. krusei* by the agar diffusion method using fluconazole as standard. Among the synthesized compounds, compound **41a** (Table [42](#Tab42){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) found to be most active against tested fungal species \[[@CR49]\].Table 42Antifungal activity of compound 41aCompoundFungal strains (ZI mm)*C. albicansC. krusei***41a**1515**Fluconazole**1920

Si et al. synthesized a series of new benzimidazole scaffolds and evaluated for their antifungal activity against *Botrytis cinerea* and *Sclerotinia sclerotiorum* using thiabendazole and azoxystrobin as references. In this series, compound **42a** exhibited excellent antifungal activity (Table [43](#Tab43){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) \[[@CR50]\].Table 43In vitro antifungal activity of compound 42aCompoundFungal strains \[EC~50~ ± SE (mg/L)\]*B. cinereaS. sclerotiorum***42a**9.75 ± 0.2318.27 ± 0.22**Thiabendazole**14.16 ± 0.2039.43 ± 0.23**Azoxystrobin**39.22 ± 0.2630.37 ± 0.28

Tahlan et al. reported a class of novel benzimidazole Schiff base derivatives and screened for its antimicrobial potency against tested microbial strains by tube dilution method. Among the synthesized compounds, **43a** and **43b** were found to be most potent antifungal agents against *A. niger* and *C. albicans* (Table [44](#Tab44){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) \[[@CR51]\].Table 44Antimicrobial results of compounds (43a--43b)CompoundsMicrobial strains (MIC = µM/mL)Bacterial strainsFungal strains*S. aureusE. coliB. subtilisP. aeruginosaS. entericaC. albicansA. niger***43a**9.629.622.412.414.812.411.20**43b**5.822.915.825.825.821.462.91**Cefadroxil**1.721.721.721.721.72----**Fluconazole**----------2.042.04

Tahlan et al. reported a series of new benzimidazole Schiff base derivatives and evaluated for its antimicrobial potency against selected microbial species. In this series, compounds **44a** and **44b** showed significant antimicrobial activity towards tested bacterial and fungal strains (Table [45](#Tab45){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) \[[@CR52]\].Table 45Antimicrobial results of compounds (44a--44b)CompoundsMicrobial strains (MIC = µM/mL)Bacterial strainsFungal strains*B. subtilisP. aeruginosaE. coliS. typhiK. pneumoniaeC. albicansA. niger***44a**1.281.281.282.555.115.112.55**44b**0.680.682.722.725.445.442.72**Cefadroxil**1.733.463.460.863.46----**Fluconazole**----------4.084.08

Yadav et al. synthesized a series of novel benzimidazole derivatives and accessed for its antimicrobial activity against *S. aureus*, *B. subtilis*, *E. coli*, *C. albicans* and *A. niger* by serial dilution method using ciprofloxacin and fluconazole as standard drugs. From the synthesized derivatives, compounds **45a** and **45b** showed excellent antimicrobial activity against selected microorganisms (Tables [46](#Tab46){ref-type="table"}, [47](#Tab47){ref-type="table"} and Fig. [9](#Fig9){ref-type="fig"}) \[[@CR53]\].Table 46Antibacterial and antifungal activities of compounds (45a--45b)CompoundsMicroorganisms (pMIC = µM/mL)*S. aureusB. subtilisE. coliC. albicansA. niger***45a**2.432.432.432.131.53**45b**2.242.241.851.941.63**Ciprofloxacin**0.190.200.28----**Fluconazole**------0.200.22 Table 47Antibacterial and antifungal activities of compounds (45a--45b)CompoundsMicroorganisms (MBC/MFC = µg/mL)*S. aureusB. subtilisE. coliC. albicansA. niger***45a**505015.625\> 50**45b**12.5503.1250\> 50**Ciprofloxacin**0.0190.0190.019----**Fluconazole**------0.0400.040

Conclusions {#Sec4}
===========

Summarizingly, after review of literature reports we concluded that benzimidazole is most promising category of bioactive heterocyclic compound that exhibit a wide variety of biological activities i.e. antimicrobial, anti-inflammatory, antiparasitic, antimalarial, antiviral, antimycobacterial, antineoplastic, antihypertensive activity etc. The present review only focus on antimicrobial activity of reported benzimidazole derivatives may serve as valuable source of information for researchers who wish to synthesize new molecules of benzimidazole nucleus which have immense potential to be investigated for newer therapeutic possibilities. Condensed information of most active compounds with their antimicrobial activity and abbreviation of microbial species and other are shown in Tables [48](#Tab48){ref-type="table"} and [49](#Tab49){ref-type="table"}, respectively.Table 48Condensed information of most active compounds with their antimicrobial activityTable 49Abbreviation of microbial species and other*Absidia corymbifera*: *A. corymbifera*Methicillin-resistant *Staphylococcus aureus*: MRSAZone of inhibition: ZI*Aspergillus clavatus*: *A. clavatus*Methicillin-resistant *Staphylococcus epidermidis*: MRSE*Aspergillus flavus*: *A. flavus*Minimum inhibitory concentration: MIC*Aspergillus fumigatus*: *A. fumigatusMicrococcus luteus*: *M. luteusAspergillus niger*: *A. niger*Multi-drug-resistant *Staphylococcus aureus*: MDRSA*Bacillus cereus*: *B. cereusMycobacterium avium*: *M. aviumBacillus megaterium*: *B. megateriumMycobacterium tuberculosis*: *M. tuberculosisBacillus proteus*: *B. proteusPenicillium chrysogenum*: *P. chrysogenumBacillus pumilus*: *B. pumilusProteus vulgaris*: *P. vulgarisBacillus subtilis*: *B. subtilisPseudomonas aeruginosa*: *P. aeruginosaBacillus typhi*: *B. typhiRhizoctoni solani*: *R. solaniBotrytis cinerea*: *B. cinereaMycobacterium kansasii*: *M. kansasiiCandida albicans*: *C. albicansSalmonella enterica*: *S. entericaCandida glabrata*: *C. glabrataSaccharomyces cerevisiae*: *S. cerevisiaeCandida krusei*: *C. kruseiSalmonella typhi*: *S. typhiCandida mycoderma*: *C. mycodermaSalmonella typhimurium*: *S. typhimuriumCandida tropicalis*: *C. tropicalisSarcina lutea*: *S. luteaCandida utilis*: *C. utilisSclerotium rolfesii*: *S. rolfesiiClostridium tetani*: *C. tetaniShigella dysenteriae*: *S. dysentriaeEberthella typhosa*: *E. typhosaStaphylococcus aureus*: *S. aureusEnterococcus faecalis*: *E. faecalisStaphylococcus epidermidis*: *S. epidermidisEscherichia coli*: *E. coliStreptococcus faecalis*: *S. faecalisFrancisella tularensis*: *F. tularensisStreptococcus mutans*: *S. mutansFusarium oxyspora*: *F. oxysporaStreptococcus pneumoniae*: *S. pneumoniaeFusarium solani*: *F. solaniStreptococcus pyogenes*: *S. pyogenesKlebsiella aerogenes*: *K. aerogenesSclerotinia sclerotiorum*: *S. sclerotiorumKlebsiella planticola*: *K. planticola*Structure activity relationship: SAR*Klebsiella pneumoniae*: *K. pneumoniaeTrichophyton mentagrophytes*: *T. mentagrophytesListeria monocytogenes*: *L. monocytogenesTrichosporon beigelii*: *T. beigelii*Minimum bactericidal concentration: MBCVancomycin-resistant *Enterococccus faecium*: VREMinimum fungicidal concentration: MFC*Vibrio cholerae*: *V. cholera*
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